Williams David Michael sold $6.8M of MRK

Merck (MRK) plans a $2.9B expansion in Montgomery County by 2030, including $550M for AI-driven research facilities, supported by a $5M state grant. The investment aims to boost vaccine and medicine production, strengthening Pennsylvania's pharmaceutical sector.

Merck will invest $2.9B to expand its Montgomery County, PA operations by 2030, including a $550M R&D facility. The state is contributing $5M. Meanwhile, the company is closing its Riverside plant, cutting jobs.

Adlai Nortye Group (Nasdaq: ANL) has partnered with Eli Lilly (NYSE: LLY) and Merck KGaA (MRK: DE) for clinical trials involving cetuximab (Erbitux). The collaboration supports Adlai Nortye's Phase I trial for AN4035, evaluating it as a monotherapy and with cetuximab in specific cancer patients. The trial is sponsored by Adlai Nortye.

Pennsylvania Governor Josh Shapiro announced $4 billion in life sciences and private-sector investments. Merck committed $2.9 billion for expansion, including $550 million for a robotics and AI facility. GSK pledged over $800 million for a biopharmaceutical hub. State and federal funds will support port expansions, totaling $837.5 million. These investments are expected to create 6,300 jobs.

Merck & Co. (MRK) reported promising results from a phase 3 skin cancer trial, showing improved survival rates with its personalized mRNA vaccine and Keytruda. The stock has a one-month return of 2.40% and a 52-week range of $82.01 to $156.92, closing at $147.37 on October 14, 2026, with a market cap of $372.30 billion. Baillie Gifford highlighted MRK in its Q3 2026 investor letter, noting the trial results.

Wall Street declines as AI spending concerns and inflation data weigh on tech stocks. CoreWeave falls 8%, extending losses amid debt concerns. AI sector weakens after Anthropic's revenue report. Semiconductor stocks also drop. Walmart gains 4% on an upgrade. September PPI rises 1.3% m/m, 6.3% y/y, above expectations, increasing Fed rate hike risks.